UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective

Heart (British Cardiac Society), 2014-07, Vol.100 (13), p.1031-1036

2014

Volltextzugriff (PDF)

EE519 Do We Need Three-State Decision Analytic Models in Metastatic Oncology? An Alternative Approach to Estimate Quality Adjusted Life Years (QALY)

Value in health, 2023-12, Vol.26 (12), p.S151

2023

Volltextzugriff (PDF)

Estimating Crossover Bias In A Randomized Clinical Trial Of Ovarian Cancer Treatment

Value in health, 2014-11, Vol.17 (7), p.A564-A564

2014

Volltextzugriff (PDF)

An Analysis of EQ-5D Quality of Life Data for a Cost-Effectiveness Analysis of Ivabradine Plus Standard Care Versus Standard Care Alone in Chronic HF

Value in health, 2013-11, Vol.16 (7), p.A533-A533

2013

Volltextzugriff (PDF)

3 dB Branch-Line Coupler with Improved Bandwidth Using PDMS and Zoflex Conductor

Advanced science letters, 2017-11, Vol.23 (11), p.11378-11381

2017

Volltextzugriff (PDF)

P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility and Overall Survival: Do We Still Need Partitioned Survival Models?

Value in health, 2022-01, Vol.25 (1), p.S11-S11

2022

Volltextzugriff (PDF)

PCN194 - Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study

Value in health, 2017-10, Vol.20 (9), p.A447-A447

2017

Volltextzugriff (PDF)

Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study

Value in health, 2017-10, Vol.20 (9), p.A447

2017

Volltextzugriff (PDF)

SA41 Novel Method for Indirect Comparison of Treatment Sequences Using Averaged Parametric Survival Models with Application to Hepatocellular Carcinoma

Value in health, 2023-12, Vol.26 (12), p.S549

2023

Volltextzugriff (PDF)

PRO62 SPINAL MUSCULAR ATROPHY: DEVELOPMENT OF NATURAL HISTORY MODELS FOR DISEASE SUBTYPES

Value in health, 2020-05, Vol.23, p.S339-S339

2020

Volltextzugriff (PDF)

PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DECISIONS IN EARLY ASSETS

Value in health, 2019-11, Vol.22, p.S770-S771

2019

Volltextzugriff (PDF)

PET-Based Instant Inkjet-Printed 4 × 4 Butler Matrix Beamforming Network

Applied Computational Electromagnetics Society journal, 2022-07, Vol.37 (2), p.199

2022

Volltextzugriff (PDF)

Impact of rooftop photovoltaic on energy demand of a building in a hot semi-arid climate

Journal of renewable and sustainable energy, 2021-11, Vol.13 (6)

2021

Volltextzugriff (PDF)

Fabrication of new conductive gels by tuning the macromolecular architectures using fluorinated acrylates

Journal of macromolecular science. Part A, Pure and applied chemistry, 2017-04, Vol.54 (4), p.249-254

2017

Volltextzugriff (PDF)

Grafting of LiAMPS on ethyl cellulose: a route to the fabrication of superior quality polyelectrolyte gels for rechargeable Lithium ion batteries

Journal of materials science, 2012-04, Vol.47 (8), p.3698-3705

2012

Volltextzugriff (PDF)

An improved cooling system design to enhance energy efficiency of floating photovoltaic systems

Journal of renewable and sustainable energy, 2020-09, Vol.12 (5)

2020

Volltextzugriff (PDF)

PRO92 ESTIMATING DISUTILITIES IN SPINAL MUSCULAR ATROPHY USING A STATED PREFERENCE SURVEY: A UK GENERAL PUBLIC STUDY

Value in health, 2020-05, Vol.23, p.S345-S345

2020

Volltextzugriff (PDF)

PRO47 SURVIVAL ESTIMATES FOR TYPE 2 SPINAL MUSCULAR ATROPHY

Value in health, 2020-05, Vol.23, p.S337-S337

2020

Volltextzugriff (PDF)

PRO93 DO CAREGIVERS AND PATIENTS VALUE THE AVOIDANCE OF LUMBAR PUNCTURES IN SPINAL MUSCULAR ATROPHY? A STATED PREFERENCE SURVEY

Value in health, 2020-05, Vol.23, p.S346-S346

2020

Volltextzugriff (PDF)

Evaluating The Clinical Effectiveness of Trastuzumab Emtansine (T-DM1) Versus All Other Treatments For Previously Treated, Unresectable, HER2-Positive Metastatic Breast Cancer (MBC): A Mixed Treatment Comparison (MTC)

Value in health, 2017-10, Vol.20 (9), p.A416

2017

Volltextzugriff (PDF)

PCN26 - Evaluating The Clinical Effectiveness of Trastuzumab Emtansine (T-DM1) Versus All Other Treatments For Previously Treated, Unresectable, HER2-Positive Metastatic Breast Cancer (MBC): A Mixed Treatment Comparison (MTC)

Value in health, 2017-10, Vol.20 (9), p.A416-A416

2017

Volltextzugriff (PDF)

PCN211 - Health Related Quality of Life in Cancer Immunotherapy: Previously Treated, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Value in health, 2017-10, Vol.20 (9), p.A450-A450

2017

Volltextzugriff (PDF)

Health Related Quality of Life in Cancer Immunotherapy: Previously Treated, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Value in health, 2017-10, Vol.20 (9), p.A450

2017

Volltextzugriff (PDF)

HEALTH STATE UTILITY VALUES FOR HER2+ METASTATIC BREAST CANCER

Value in health, 2017-05, Vol.20 (5), p.A115

2017

Volltextzugriff (PDF)

NON-PROPORTIONAL HAZARDS. EXTRAPOLATING RELATIVE TREATMENT EFFECTS BEYOND OBSERVED DATA WITH CANCER IMMUNOTHERAPIES

Value in health, 2017-05, Vol.20 (5), p.A325

2017

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(72)
Koreanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective

EE519 Do We Need Three-State Decision Analytic Models in Metastatic Oncology? An Alternative Approach to Estimate Quality Adjusted Life Years (QALY)

Estimating Crossover Bias In A Randomized Clinical Trial Of Ovarian Cancer Treatment

An Analysis of EQ-5D Quality of Life Data for a Cost-Effectiveness Analysis of Ivabradine Plus Standard Care Versus Standard Care Alone in Chronic HF

3 dB Branch-Line Coupler with Improved Bandwidth Using PDMS and Zoflex Conductor

P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility and Overall Survival: Do We Still Need Partitioned Survival Models?

PCN194 - Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study

Rate of Hospitalization Due To Adverse Event and Length of Stay for Atezolizumab in Second and Third Line Metastatic Non-Small Lung Cancer (NSCLC) Using Phase 3 Oak Study

SA41 Novel Method for Indirect Comparison of Treatment Sequences Using Averaged Parametric Survival Models with Application to Hepatocellular Carcinoma

PRO62 SPINAL MUSCULAR ATROPHY: DEVELOPMENT OF NATURAL HISTORY MODELS FOR DISEASE SUBTYPES

PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DECISIONS IN EARLY ASSETS

PET-Based Instant Inkjet-Printed 4 × 4 Butler Matrix Beamforming Network

Impact of rooftop photovoltaic on energy demand of a building in a hot semi-arid climate

Fabrication of new conductive gels by tuning the macromolecular architectures using fluorinated acrylates

Grafting of LiAMPS on ethyl cellulose: a route to the fabrication of superior quality polyelectrolyte gels for rechargeable Lithium ion batteries

An improved cooling system design to enhance energy efficiency of floating photovoltaic systems

PRO92 ESTIMATING DISUTILITIES IN SPINAL MUSCULAR ATROPHY USING A STATED PREFERENCE SURVEY: A UK GENERAL PUBLIC STUDY

PRO47 SURVIVAL ESTIMATES FOR TYPE 2 SPINAL MUSCULAR ATROPHY

PRO93 DO CAREGIVERS AND PATIENTS VALUE THE AVOIDANCE OF LUMBAR PUNCTURES IN SPINAL MUSCULAR ATROPHY? A STATED PREFERENCE SURVEY

Evaluating The Clinical Effectiveness of Trastuzumab Emtansine (T-DM1) Versus All Other Treatments For Previously Treated, Unresectable, HER2-Positive Metastatic Breast Cancer (MBC): A Mixed Treatment Comparison (MTC)

PCN26 - Evaluating The Clinical Effectiveness of Trastuzumab Emtansine (T-DM1) Versus All Other Treatments For Previously Treated, Unresectable, HER2-Positive Metastatic Breast Cancer (MBC): A Mixed Treatment Comparison (MTC)

PCN211 - Health Related Quality of Life in Cancer Immunotherapy: Previously Treated, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Health Related Quality of Life in Cancer Immunotherapy: Previously Treated, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

HEALTH STATE UTILITY VALUES FOR HER2+ METASTATIC BREAST CANCER

NON-PROPORTIONAL HAZARDS. EXTRAPOLATING RELATIVE TREATMENT EFFECTS BEYOND OBSERVED DATA WITH CANCER IMMUNOTHERAPIES

Suchergebnisse filtern